| Citation: |
HUANG Lei, LIU Liwen, LING Yanzhi, TU Junrong, LI Qi, HU Mingzhu. Efficacy and safety of ferric derisomaltose in the treatment of iron deficiency anemia caused by abnormal uterine bleeding[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 123-126. DOI: 10.7619/jcmp.20231602
|
To evaluate the efficacy and safety of ferric derisomaltose in the treatment of iron deficiency anemia associated with abnormal uterine bleeding (AUB).
The data of sixty-four patients with iron deficiency anemia caused by AUB were retrospectively analyzed. According to the use of anti-anemia drugs, the patients were divided into ferric derisomaltose group (n=21), oral iron supplementation group (n=20) and iron sucrose group (n=23). The iron isomaltose group was treated with iron isomaltose injection, the oral iron prescription group was treated with iron protein succinate oral solution or ferrous succinate tablet, and the iron sucrose group was treated with iron sucrose injection. The changes of hemoglobin (Hb) and serum ferritin (SF) were observed at baseline and at the 3rd day, 4th and 12th week of treatment. The incidences of common adverse events, such as allergic reactions and gastrointestinal reactions during treated by iron isomaltose, oral iron supplementation and iron sucrose were compared.
At the 4th and 12th week of treatment, Hb levels in the ferric derisomaltose group was higher than those of the oral iron supplementation group and iron sucrose group (P < 0.05). The incidence of adverse events was the lowest in the ferric derisomaltose group and the highest in the oral iron group. The main adverse events in the ferric derisomaltose group were infusion-related adverse reactions, which were mild and did not require additional treatment, and had no effect on compliance.
For patients with anemia caused by uterine hemorrhage, treatment with ferric derisomaltose could result in increase of Hb and SF, and this beneficial effect can last for at least 12 weeks with low incidence of adverse reaction and good tolerance.
| [1] |
中国营养学会"缺铁性贫血营养防治专家共识"工作组. 缺铁性贫血营养防治专家共识[J]. 营养学报, 2019, 41(5): 417-426. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXX201905004.htm
|
| [2] |
OWAIDAH T, AL-NUMAIR N, AL-SULIMAN A, et al. Iron deficiency and iron deficiency Anemia are common epidemiological conditions in Saudi Arabia: report of the national epidemiological survey[J]. Anemia, 2020, 2020: 6642568.
|
| [3] |
COOK J D, REDDY M B. Efficacy of weekly compared with daily iron supplementation[J]. Am J Clin Nutr, 1995, 62(1): 117-120. doi: 10.1093/ajcn/62.1.117
|
| [4] |
杨辰, 周道斌. 缺铁性贫血的诊治及铁剂发展历程[J]. 临床药物治疗杂志, 2021, 19(8): 18-22. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYW202108005.htm
|
| [5] |
TOLKIEN Z, STECHER L, MANDER A P, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(2): e0117383. doi: 10.1371/journal.pone.0117383
|
| [6] |
中华医学会血液学分会红细胞疾病(贫血)学组. 铁缺乏症和缺铁性贫血诊治和预防的多学科专家共识(2022年版)[J]. 中华医学杂志, 2022, 102(41): 3246-3255.
|
| [7] |
吴德沛, 宣建伟. 蔗糖铁治疗缺铁性贫血的真实世界研究[J]. 临床药物治疗杂志, 2022, 20(7): 32-39. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYW202207006.htm
|
| [8] |
李莉娟, 张连生. 缺铁性贫血规范化诊治的若干问题[J]. 中华医学杂志, 2021, 101(40): 3266-3270.
|
| [9] |
AVNI T, BIEBER A, GROSSMAN A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis[J]. Mayo Clin Proc, 2015, 90(1): 12-23.
|
| [10] |
DERMAN R, ROMAN E, MODIANO M R, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia[J]. Am J Hematol, 2017, 92(3): 286-291.
|
| [11] |
KALRA P A, BHANDARI S, SAXENA S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia[J]. Nephrol Dial Transplant, 2016, 31(4): 646-655.
|
| [12] |
POLLOCK R F, BIGGAR P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia[J]. Expert Rev Hematol, 2020, 13(2): 187-195.
|
| [13] |
KOCH T A, MYERS J, GOODNOUGH L T. Intravenous iron therapy in patients with iron deficiency Anemia: dosing considerations[J]. Anemia, 2015, 2015: 763576.
|
| [14] |
PONIKOWSKI P, VOORS A A, ANKER S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2016, 37(27): 2129-2200.
|
| [15] |
BREYMANN C, AUERBACH M. Iron deficiency in gynecology and obstetrics: clinical implications and management[J]. Hematology Am Soc Hematol Educ Program, 2017, 2017(1): 152-159.
|
| [16] |
AUERBACH M, GAFTER-GVILI A, MACDOUGALL I C. Intravenous iron: a framework for changing the management of iron deficiency[J]. Lancet Haematol, 2020, 7(4): e342-e350.
|
| [17] |
中华医学会血液学分会红细胞疾病(贫血)学组. 静脉铁剂应用中国专家共识(2019年版)[J]. 中华血液学杂志, 2019, 40(5): 358-362.
|
| [18] |
AAPRO M, BEGUIN Y, BOKEMEYER C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2018, 29(Suppl 4): iv271.
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: